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Abstract
Background: Hypertensive patients with reduced blood pressure fall (BPF) at night are at higher risk of
cardiovascular events (CVE).
Methods: We evaluated in hypertensive diabetic patients, if a reduced nocturnal BPF can precedes the
development of diabetic nephropathy (DN). We followed 70 patients with normal urinary albumin excretion (UAE)
for two years. We performed 24-hours ambulatory BP monitoring in baseline and at the end of the study.
Results: Fourteen (20%) patients (GI) developed DN (N = 11) and/or CVE (n = 4). Compared to the remaining
56 patients (GII) in baseline, GI had similar diurnal systolic (SBP) and diastolic BP (DBP), but higher nocturnal SBP
(138 ± 15 vs 129 ± 16 mmHg; p < 0.05) and DBP (83 ± 12 vs 75 ± 11 mmHg; p < 0,05). Basal nocturnal SBP correlated
with occurrence of DN and CVE (R = 0.26; P < 0.05) and with UAE at the end of the study (r = 0.3; p < 0.05). Basal BPF
(%) correlated with final UAE (r = -0.31; p < 0.05). In patients who developed DN, reductions occurred in nocturnal
systolic BPF (12 ± 5 vs 3 ± 6%, p < 0,01) and diastolic BPF (15 ± 8 vs 4 ± 10%, p < 0,01) while no changes were
observed in diurnal SBP (153 ± 17 vs 156 ± 16 mmHg, NS) and DBP (91 ± 9 vs 90 ± 7 mmHg, NS). Patients with final
UAE < 20 μg/min, had no changes in nocturnal and diurnal BP.
Conclusions: Our results suggests that elevations in nocturnal BP precedes DN and increases the risk to develop
CVE in hypertensive patients with T2DM.
Background
Cardiac disease is a common cause of death in patients
with DM [1,2]. Predictors of all-causes of mortality in
type 1 and 2 diabetics include systolic blood pressure,
co-existent cardiovascular disease, and presence of
microvascular complications [3-5]. Microalbuminuria is
also a marker of cardiac risk and has been related to
higher risk of mortality in certain age groups [4].
We have demonstrated that nocturnal systolic blood
pressure fall (BPF) is lower in T2DM when compared with
essential hypertensives and it is related to left ventricular
hypertrophy [6] and diabetic retinopathy [7]. In addition,
hypertension and renal impairment in diabetes are linked
and it has been reported that hypertensive non-diabetic
patients who lack the normal nocturnal decline in blood
pressure (’non-dippers’) have an increased incidence of
cardiovascular complications [8-12]. Therefore, it is a rea-
sonable hypothesis that a reduced BPF during the night
could precedes the development of diabetic nephropathy.
Its well known that 24-hours ambulatory BP monitor-
ing (24-h ABPM) has previously identified variations in
blood pressure profile in patients with essential hyper-
tension and diabetes and it is related to cardiac events
[13-15]. The objective of our study was to evaluate, in
hypertensive patients with T2DM, if a reduced sleep
BPF predicts the development of diabetic nephropathy.
Methods
Patients
The inclusion criteria were: age between 30-70 years,
hypertensives with T2DM not treated with insulin
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before, normal values of urinary protein excretion, crea-
tinine and urinary albumin excretion. The exclusion cri-
teria were: history of congestive heart failure and angina
pectoris; cardiac valvulopathy evaluated by echocardio-
graphy (ECHO) and history of previous cardiovascular
events. Myocardial infarction, stroke, angina pectoris
were considered as cardiovascular events. This study
was approved by Ethics Committee.
We followed 70 T2DM hypertensive patients
(32 males and 38 females) with both normal urinary
protein excretion (UPE), urinary albumin excretion
(UAE), excretion glomerular filtration rate (eGFR) and
serum Cr (Cr), submitted to 24 h-ABPM, during a per-
iod of two years. Those patients were recruited from
Diabetes and Hipertension ambulatory of Federal
University of São Paulo.
At baseline all patients were submitted to 24 h-ABPM,
ECHO, UPE, UAE, Cr, fasting blood glucose (FBG), cho-
lesterol (TC), triglycerides (TG) and office BP. Every
three months Cr, FBG, TC and fractions, and office BP
were repeated. UPE was performed every six months.
All patients who developed abnormal proteinuria during
the study also had performed UAE. And at the end of
the study (2 years follow-up), patients repeated ABPM,
UEA and UPE. The development of CVE, and DN,
defined as abnormal UPE (confirmed by also abnormal
UAE) were considered as end points.
Criteria for established hypertension were systolic and
diastolic blood pressure ≥ 140/90 mmHg on repeated
measurements [7]. All T2DM patients were treated with
diet plus oral hypoglycemic agents. No patient used
insulin during the study. Diabetes was diagnosed
acoording to the standard criteria. Type 2 DM were
identified as those with disease onset at the age of 30
years or after and no need of insulin teatment [6].
The average of FBG, chosen in this study, has been
commonly used to monitor glycemic control in type 2
diabetics treated with diet alone or oral hypoglycemic
agents. According to several studies, the retrospective
average of FBG values is considered a good index to
establish a previous long-term glycemic control on those
patients [6].
Diabetic Nephropathy was established by microalbumi-
nuria, according to the Gentoften-Montecatini conven-
tion [16]. It was considered present when the UAE in a
24-h urine or a short-time collected urine during daytime
was in the range of 30-300 mg/24 h (20-200 μ g/min).
The upper range was corresponding to a UPE of approxi-
mately 0,5 g/l, which was previously considered to be the
first marker of clinical diabetic nephropathy [17]. It has
been well established that microalbuminuria predicts
overt nephropathy in type 1 diabetics. The UAE and UPE
are well-documented parts of monitoring those patients
[18]. Some surveys also showed benefits on performing
these methods in type 2 patients. Microalbuminuria can
predicts not only overt renal disease, but also mortality in
this population, that is why we opted to perform both
methods in this study [17].
24-h Ambulatory blood-pressure monitoring
24-h ABPM was performed using a Spacelabs - 90207
automatic cuff-oscillometric devices (Spacelabs, Inc.
Redmond, WA-USA) after 15 days washout of all anti-
hypertensive drugs, after that all subjects restarted on
their antihypertensive medications. The monitor was
installed in the morning period and it was drop out
after 24 hours. The individuals were oriented to keep
their regular activities and make a report discriminating
the hours of each activity. The device was programmed
to perform four measures during each hour. It was
established an average systolic and diastolic pressure,
during diurnal period, nocturnal period and in 24 hours.
For the purpose of ambulatory blood-pressure monitor-
ing, two different periods were defined. The daytime per-
iod included all readings obtained from 8 a.m. until 8 p.m.,
and the night time period included all readings from 8 pm
until 8 a.m. Measures of systolic BP higher than 260
mmHg and diastolic BP higher than 150 mmHg were
excluded. The limit to detection of heart rate was between
200 and 20 bpm. The exam was accepted if at least 75% of
the measures in 24 hours were successfully executed.
Moreover, it was calculated the nocturnal BPF ({diurnal
systolic BP - nocturnal systolic BP} × 100/diurnal systolic
BP). It was considered normal values of nocturnal systolic
BPF greater than 10% (dippers). Patients that showed
BPF lower than this value were called “non-dippers”.
Echocardiography
M-mode, two-dimensional echocardiographic and car-
diac Doppler studies were performed using a commer-
cially available echo-Doppler unit (Esaote Biomedica,
Florence, Italy; model SIM 5000) equipped with a 2,
5 MHz mechanical transducer. It was performed with
patients in the partial left lateral supine position.
M-mode measurements were performed according to
the recommendations of American Society of Echocar-
diography. Left ventricular mass (LVM) was calculated
as previously recommended by Devereaux et al [19].
The LVM index was calculated by dividing LVM by the
body surface area. All examinations were analyzed by
the same echocardiographer that was blinded to the
dipping status. Transmitral blood flow signals were
obtained on top of mitral valve by apical 4-chamber-
view. All measurements of diastolic function were done
with normal heart rate (60-100 bpm).
Urinary 24 h-proteinuria and serum creatinine
UPE was performed through Kingsbury sulfosalicilic
method adapted by Morales and Merino that has normal
values below 150 mg in 24 hours. The Cr was determined
through Jaffé technique modified by Bartels et al [20].
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Urinary albumin excretion
UAE was determined by a turbidimetric immunoassay
kit. Microalbuminuria was defined by the presence of a
UAE rate consistently between 20 and 200 mg/min, as
assessed by three 24-h urine samples collected at least
6 weeks after any urinary tract infections or acute
hyperglycemic events, and after exclusion of all other
causes of albuminuria [21].
Long term glycemic control
To create a measure of the previous long-term glycemic
control, the average of all FG values available before the
study was calculated. If several FG values were recorded
during a month, only the first value of the month was
used. The same procedure was used to calculate pre-
vious indexes of office BP, TC and fractions, and TG.
These indices were referred to as the basal average of
FG, office BP, TC and fractions, and TG values; and did
not differ between the groups.
Statistical Analysis
All normally distributed values were given as mean
± SD and all other values were given as median
(range). In comparison of the non-normally distribu-
ted variables, the Mann-Whitney test was used to
test the differences between two groups and Wil-
coxon test was used to compare the same groups
before and after the follow up period. For all nor-
mally distributed variables, the unpaired student’s
test was used for comparison between two groups
and paired student’s test was used to compare the
same groups before and after. For correlation analy-
sis, correlation coefficients (Pearson or Spearman)
were calculated. A P value (two tailed) less than
0.05 was considered statistically significant. All cal-
culations were made with a commercially available
program, SigmaStat 1.0 (Jandel Scientific Corpora-
tion, Chicago, Illinois).
Results
Fourteen (20%) patients (GI) developed DN (N = 11)
and/or CVE (n = 4). One patient who presented CVE
also had DN. Initially, when compared with group of
the remaining 56 patients (GII). Group I had similar
values of Cr and mean diurnal systolic (SBP) and diasto-
lic blood pressure (DBP) but higher basal levels of both
nocturnal SBP (138 ± 15 vs 129 ± 16 mmHg; p < 0.05)
and DBP (83 ± 12 vs 75 ± 11 mmHg; p < 0,05)
(TABLE 1). In addition, no diference was found between
the two groups in relation to the types of antihiperten-
sives used during this study.
Table 1 Groups in the baseline according development of
cardiovascular events and or diabetic nephropathy
during the study
BASELINE GI (n = 14) GII (n = 56) P
Age (years) 57 ± 11 58 ± 8 N.S
BMI (kg/m2) 29 ± 5 28 ± 4 N.S
AFBG (mg/dl) 166 ± 38 156 ± 37 N.S
HbA1c (%) 8,6 ± 2,2 8,8 ± 2,5 N.S
DSBP (mmHg) 151 ± 15 144 ± 17 N. S
DDBP (mmHg) 95 ± 12 89 ± 11 N.S
NSBP (mmHg) 138 ± 15 129 ± 16 < 0.05
NDBP (mmHg) 83 ± 12 75 ± 11 < 0.05
SBPF (%) 8 ± 4 10 ± 6 N.S
DBPF (%) 13 ± 6 15 ± 7 N.S
DSBP: Diurnal Systolic Blood Pressure
DDBP: Diurnal Diastolic Blood Pressure
NSBP: Nocturnal Systolic Blood Pressure
NDBP: Nocturnal Diastolic Blood Pressure
SBPF: Systolic Blood Pressure Fall
DBPF: Diastolic Blood Pressure Fall
GI: Patients who presented DN and/or CVE
GII: Patients who did not present DN and/or CVE
AFBG: average of fasting blood glucose values
HbA1c: glycated hemoglobin
Table 2 Variations of blood pressure and occurrence of diabetic nephropathy
BASAL GI (n = 11) FINAL p BASAL GII (n = 56) FINAL P
DSBP (mmHg) 153 ± 17 156 ± 16 > 0.1 146 ± 14 147 ± 12 > 0.1
DDBP (mmHg) 91 ± 9 90 ± 7 > 0.1 91 ± 12 92 ± 10 > 0.1
NSBP (mmHg) 135 ± 12 152 ± 19 < 0.05 130 ± 13 134 ± 19 > 0.1
NDBP (mmHg) 77 ± 9 86 ± 10 < 0.05 79 ± 11 80 ± 11 > 0.1
SBPF (%) 12 ± 5 3 ± 6 < 0.05 11 ± 4 9 ± 8 > 0.1
DBPF (%) 15 ± 8 4 ± 10 < 0.05 11 ± 8 13 + 9 > 0.1
DSBP: Diurnal Systolic Blood Pressure
DDBP: Diurnal Diastolic Blood Pressure
NSBP: Nocturnal Systolic Blood Pressure
NDBP: Nocturnal Diastolic Blood Pressure
SBPF: Systolic Blood Pressure Fall
DBPF: Diastolic Blood Pressure Fall
GI A: Patients who developed DN at the end of the study and also had 24-h ABPM performed after 2 years
GI B: Patients who did not develop DN at the end of the study and also had 24-h ABPM performed after 2 years
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Basal nocturnal SBP values correlated with both the
occurrence of DN and CVE (r = 0.26; p < 0.05) and with
UAE, determined at the end of the study (r = 0,3; p < 0.05).
The basal BPF (%) also showed correlation with final
UAE (r = - 0.31; p < 0.05). In patients who developed DN
an elevation of nocturnal BP was observed during the
study period. In this group, significant reductions were
detected in both nocturnal systolic BPF (12 ± 5 vs 3 ±6%,
p < 0,01) and diastolic BPF (15 ± 8 vs 4 ± 10%, p < 0,01)
while no changes were observed in diurnal SBP (153 ± 17
vs 156 ± 16 mmHg, NS) and DBP (91 ± 9 vs 90 ±
7 mmHg, NS) (TABLE 2, FIGURE 1, FIGURE 2). In the
remaining patients, who did not develop DN, with basal
and final ABPM determined, no changes were detected
in both nocturnal and diurnal BP values and BPF
(TABLE 2).
Discussion
In our prospective study, hypertensive normoalbuminu-
ric patients with type 2 DM showed higher basal levels
of both nocturnal systolic and diastolic blood pressure
preceding the development of CVE and/or abnormal
albuminuria. In addition, patients who evolved to micro
or macroalbuminuria also showed an increase in noctur-
nal systolic and diastolic BP and lower BPF at the end of
the two years follow up. Patients who remained nor-
moalbuminurics after 2 years did not presented any
change in 24-h ABPM profile.
Figure 1 Variations of nocturnal blood pressure and occurrence of diabetic nephropathy. * p < 0.05 vs basal. NSBP: Nocturnal Systolic
Blood Pressure. NDBP: Nocturnal Diastolic Blood Pressure
Figure 2 Variations of diurnal blood pressure and occurrence of diabetic nephropathy. DSBP: Diurnal Systolic Blood Pressure. DDBP:
Diurnal Diastolic Blood Pressure
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An inversion of day-night BP profile was demon-
strated to be related to renal damage in Diabetes
[22,23]. Lurbe et al have found that in subjects with
type 1 diabetes, elevated systolic BP during sleep pre-
cedes the development of microalbuminuria [23]. This
abnormality in nocturnal BP should be more a cause
than a consequence of diabetic nephropathy. Palmas
et al have reported that nocturnal BP elevation predicts
progression of albuminuria in elderly people with type 2
Diabetes [24]. As we are aware, our study is the first to
demonstrate that an elevation of both nocturnal systolic
and diastolic BP could also precede microalbuminuria in
hypertensives withT2DM.
Autonomic neuropathy (AN) could be a via through
hyperglycemia would elevate nocturnal SBP levels. Some
studies have related AN to an increase of left ventricular
mass and to the loss of nocturnal BP decrease [25].
Other conditions, such obstructive sleep apnea and
renal failure with fluid retention might be involved [26].
Whatever its mechanisms might be, the increase of sys-
tolic nocturnal BP and or lack of normal nocturnal BP
fall have been related to chronic complications in dia-
betic patients [27].
There are a few limitations of 24-h ABPM technique
in diabetic patients. One of the main problems is the
necessity of validation studies of each oscillometric
device. We recently tested and retested the Spacelabs -
90207 automatic cuff-oscillometric devices (Spacelabs,
Inc. Redmond, WA-USA) in hypertensive type 2 diabetic
patients [28] and we found that it is a reliable method
to clinical management of those patients. An obstacle
that remains is the high price and limited availability of
24-h ABPM devices in general practice. Another pro-
blem is the definition of 24-h ABPM cut-offs for hyper-
tension diagnosis and therapeutic goals in type 2 DM.
We recently also described that diabetic patients with
nocturnal systolic BP ≥ 140 mmHg had a great increase
on prevalence of left ventricular hypertrophy (LVH) [6].
Furthermore, Staessen et al [29], in a meta-analysis of
23 studies, including a total of 3,476 normal subjects,
concluded that only levels ≥ 137 mmHg for nocturnal
SBP should be considered as definite hypertension. This
nocturnal SBP value is very close to the level that we
found to start increasing the risk of LVH. Unfortunately,
our relative small number of patients did not allowed to
calculate thresholds and achieve a consistent multivari-
ate analysis
According to Parati et al [30], a noninvasive and
powerful test such as 24-h ABPM could be useful in
every diabetic subject. However, given the limited avail-
ability of this test in daily practice, the author suggests
that performing 24-h ABPM or not, should be evaluated
on case-by-case basis, evaluating some key and risk fac-
tors such previous clinical events (stroke and myocardial
infarction) and the presence of impaired renal function.
In our opinion, the presence of hypertension per se in
diabetic patients must be an indication to perform 24 h-
ABPM. The cost must be reduced to that approach be
possible.
It has been pointed out the importance of cardiometa-
bolic risk factors in hypertensive patients [31]. Belletti et
al found that as compared to hypertensive patients with-
out any additional cardiometabolic risk factors, those
with diabetes, obesity and hyperlipidemia were less likely
to have controlled BP. In our study, the groups did not
differ in body mass index, diabetes control and in the
kind of antihypertensive treatment. In addition, the rela-
tion between hyperlipidemia and development of dia-
betic nephropathy is not clear. Nevertheless, it is
possible that some of these variables, as confounders,
could be involved in elevation of nocturnal blood pres-
sure and evolution to diabetic nephropathy.
Conclusions
In summary, our study suggests that an elevation of noc-
turnal systolic blood pressure and a loss of nocturnal
blood pressure fall might precede the development of
diabetic nephropathy and cardiovascular events in hyper-
tensive normoalbuminuric patients with type 2 diabetes.
Other studies are necessary to confirm these findings.
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